{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:11Z","timestamp":1787181911066,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}],"id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","award":["Program EXCELES"],"award-info":[{"award-number":["Program EXCELES"]}],"id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agentura na podporu vyskumu a vyvoja Slovenskej republiky","doi-asserted-by":"publisher","award":["APVV-24-0168"],"award-info":[{"award-number":["APVV-24-0168"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agentura na podporu vyskumu a vyvoja Slovenskej republiky","doi-asserted-by":"publisher","award":["APVV-24-0333"],"award-info":[{"award-number":["APVV-24-0333"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["VEGA 2\/0059\/25"],"award-info":[{"award-number":["VEGA 2\/0059\/25"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002002","name":"Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119839","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:13:36Z","timestamp":1786220016000},"page":"119839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic targeting of folate receptor alpha (FR\u03b1) by antibody-polymer-drug conjugate in testicular germ cell tumors"],"prefix":"10.1016","volume":"202","author":[{"given":"Lucia","family":"Ku\u010derov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-2016","authenticated-orcid":false,"given":"Robert","family":"Pola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Filipov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stehl\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kl\u00e1ra","family":"Dr\u017e\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia","family":"Udvorkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Luk\u00e1\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9811-0399","authenticated-orcid":false,"given":"Adriana","family":"Fekia\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavl\u00edna","family":"Malch\u00e1rkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg\u00edna","family":"Koln\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"\u010cierna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok K.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Etrych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119839_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316872","article-title":"Biomarkers for salvage therapy in testicular germ cell tumors","volume":"24","author":"Urbini","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119839_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41585-022-00683-1","article-title":"High-dose chemotherapy for relapsed testicular germ cell tumours","volume":"20","author":"Chovanec","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.biopha.2026.119839_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.urolonc.2015.01.025","article-title":"Salvage high-dose chemotherapy for germ cell tumors","volume":"33","author":"Feldman","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.biopha.2026.119839_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061845","article-title":"Target antigen attributes and their contributions to clinically approved antibody-drug conjugates (ADCs) in haematopoietic and solid cancers","volume":"15","author":"Esapa","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119839_bib5","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s11912-024-01576-9","article-title":"Exploring the role of target expression in treatment efficacy of antibody-drug conjugates (ADCs) in solid cancers: a comprehensive review","volume":"26","author":"Mathiot","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119839_bib6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1158\/2159-8290.CD-24-0088","article-title":"Elucidating the cell surfaceome to accelerate cancer drug deVELOPment","volume":"14","author":"Geri","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119839_bib7","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s43018-021-00282-w","article-title":"The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets","volume":"2","author":"Hu","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2026.119839_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10020-023-00636-3","article-title":"Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options","volume":"29","author":"Skowron","year":"2023","journal-title":"Mol. Med."},{"key":"10.1016\/j.biopha.2026.119839_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118659","article-title":"Therapeutic efficacy of sacituzumab govitecan in recurrent refractory germ cell tumors","volume":"192","author":"Udvorkova","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119839_bib10","doi-asserted-by":"crossref","first-page":"C362","DOI":"10.1152\/ajpcell.00200.2024","article-title":"Antibody-drug conjugates as a novel therapeutic modality to treat recurrent refractory germ cell tumors","volume":"327","author":"Udvorkova","year":"2024","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.biopha.2026.119839_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor alpha in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119839_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2470309","article-title":"Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age","volume":"17","author":"Liu","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2026.119839_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells14040287","article-title":"Mirvetuximab soravtansine induces potent cytotoxicity and bystander effect in cisplatin-resistant germ cell tumor cells","volume":"14","author":"Kucerova","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119839_bib14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nbt.3274","article-title":"Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading","volume":"33","author":"Strop","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119839_bib15","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119839_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2017.02.034","article-title":"A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas","volume":"103","author":"Zhang","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119839_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28062605","article-title":"Antibody-biopolymer conjugates in oncology: a review","volume":"28","author":"Chavda","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119839_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202300377","article-title":"Organic-solvent-free \"Lego-Like\" modular preparation of fab-nondestructive antibody-drug conjugates with ultrahigh drug-to-antibody ratio","volume":"35","author":"Liu","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biopha.2026.119839_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0168-3659(01)00330-3","article-title":"Water soluble polymers in tumor targeted delivery","volume":"74","author":"Kopecek","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119839_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-3659(99)00141-8","article-title":"Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation","volume":"64","author":"Ulbrich","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119839_bib21","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/macp.1977.021780803","article-title":"Aminolyses of monomeric and polymeric 4-nitrophenyl esters of N-methacryloylamino acids","volume":"178","author":"Rejmanov\u00e1 P","year":"1977","journal-title":"Makromol. Chem."},{"key":"10.1016\/j.biopha.2026.119839_bib22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/acs.biomac.8b01616","article-title":"Polymer cancerostatics targeted by recombinant antibody fragments to GD2-positive tumor cells","volume":"20","author":"Pola","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biopha.2026.119839_bib23","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1039\/D1PY00707F","article-title":"The role of the biotin linker in polymer antibody mimetics, iBodies, in biochemical assays","volume":"12","author":"\u0160ubr V","year":"2021","journal-title":"Polym. Chem."},{"key":"10.1016\/j.biopha.2026.119839_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1959","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2026.119839_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113876","article-title":"Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas","volume":"384","author":"Lidicky","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119839_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084263","article-title":"Targeting of deregulated Wnt\/beta-Catenin Signaling by PRI-724 and LGK974 inhibitors in germ cell tumor cell lines","volume":"22","author":"Schmidtova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119839_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122999","article-title":"NLRP7 promotes choriocarcinoma growth and progression through the establishment of an immunosuppressive microenvironment","volume":"13","author":"Reynaud","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119839_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/03008916251408266","article-title":"Choriocarcinoma: diagnosis, treatment and management of a rare germ cell tumour. An update review","volume":"112","author":"Francesco","year":"2026","journal-title":"Tumori"},{"key":"10.1016\/j.biopha.2026.119839_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-026-03484-0","article-title":"G.U.T. Global society for rare, risk factors and causes of early death in germ cell tumors: a global society for rare GU tumors study","author":"Mego","year":"2026","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119839_bib30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fendo.2019.00218","article-title":"Severe complications in testicular germ cell tumors: the choriocarcinoma syndrome","volume":"10","author":"Rejlekova","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2026.119839_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00428-025-04243-x","article-title":"Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study","volume":"488","author":"Ricci","year":"2026","journal-title":"Virchows Arch."},{"key":"10.1016\/j.biopha.2026.119839_bib32","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/curroncol31040172","article-title":"Antibody-drug conjugates in the treatment of genitourinary cancers: an updated review of data","volume":"31","author":"Nathan","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.biopha.2026.119839_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tiv.2017.12.003","article-title":"Evaluation of the effects of antiepileptic drugs on folic acid uptake by human placental choriocarcinoma cells","volume":"48","author":"Kurosawa","year":"2018","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.biopha.2026.119839_bib34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-025-01686-2","article-title":"Mirvetuximab soravtansine: current and future applications","volume":"18","author":"Kong","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119839_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122285","article-title":"Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy","volume":"301","author":"Zhang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119839_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0308604","article-title":"Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis","volume":"19","author":"Kathad","year":"2024","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119839_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119839_bib38","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1054\/bjoc.2001.1884","article-title":"An orthotopic xenograft model of human nonseminomatous germ cell tumour","volume":"85","author":"Douglas","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119839_bib39","first-page":"3593","article-title":"Lymphoma transformation of tumor infiltrating lymphocytes observed in testicular patient\u2011derived xenograft models","volume":"40","author":"Kalavska","year":"2018","journal-title":"Oncol. Rep."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:53:20Z","timestamp":1787180000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S0753332226008759"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119839","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of folate receptor alpha (FR\u03b1) by antibody-polymer-drug conjugate in testicular germ cell tumors","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119839"}}